KPV Peptide and Gut Inflammation: Evidence and Safety

KPV—lysine-proline-valine—is a three-amino-acid sequence corresponding to the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH). Researchers have studied free KPV and KPV delivery systems in intestinal cells and animal models of colitis. Those experiments are interesting, but they do not establish a treatment for inflammatory bowel disease, gastritis, cancer, or “leaky gut” in humans.

No published human clinical trial has established that KPV treats ulcerative colitis, Crohn’s disease, gastritis, repairs the stomach lining, or prevents colorectal cancer. In its July 2026 evaluation, FDA reported that it had not identified clinical studies or human exposure data for KPV by any route of administration.

The short answer

• The direct KPV evidence summarized here is preclinical. It comes from cultured intestinal and immune cells, chemically induced colitis in mice or rats, and experimental nanoparticle or hydrogel delivery systems.
• The studies primarily concern the colon, not the stomach. Calling the findings “stomach lining repair” changes both the organ and the evidence.
• Formulation is part of the experiment. Results from KPV encapsulated in targeted nanoparticles and a chitosan-alginate hydrogel cannot be assigned to an ordinary capsule, nasal spray, topical product, or injectable vial.
• Human effectiveness and safety remain unknown. A lack of adverse-event reports is not proof of safety when human exposure has not been characterized.
• KPV is not an FDA-approved drug. FDA proposed in July 2026 that KPV free base and KPV acetate not be added to the section 503A Bulks List; that proposal is not itself a drug-approval decision.

What is KPV?

KPV is the tripeptide Lys-Pro-Val. It corresponds to residues 11–13 at the C-terminus of α-MSH, a 13-amino-acid melanocortin peptide. Laboratory research has associated this short sequence with some of α-MSH’s anti-inflammatory activity.

That biochemical relationship does not mean a commercial KPV product is a naturally occurring medicine or is interchangeable with α-MSH. Sequence, terminal chemistry, salt form, formulation, impurities, concentration, and route all affect what material was studied and what conclusions can follow.

See the KPV profile for a compound-level summary. For a broader comparison of repair claims, use the healing-peptides evidence guide.

Evidence map

What the cell and mouse studies show

PepT1-mediated uptake and inflammatory signaling

A 2008 study used intestinal epithelial cell lines, Jurkat T cells, and two chemically induced mouse-colitis models. In the cell experiments, KPV uptake involved the proton-coupled oligopeptide transporter PepT1. KPV exposure was associated with reduced activation of NF-κB and MAPK pathways and lower secretion or expression of several pro-inflammatory cytokines.

Oral KPV also reduced selected histologic and inflammatory measures in DSS- and TNBS-induced mouse colitis. These models are tools for studying injury and inflammation; they do not reproduce the full biology, treatment history, or clinical outcomes of ulcerative colitis or Crohn’s disease in people.

Mechanistic terms such as “NF-κB inhibition” can sound clinically decisive, but pathway changes are intermediate measurements. They do not tell us whether a person feels better, achieves endoscopic remission, avoids hospitalization, or experiences an acceptable long-term safety profile.

Nanoparticles and hydrogel delivery

A 2010 study encapsulated KPV in polymeric nanoparticles and then placed those particles inside an alginate-chitosan hydrogel intended to release in the colon. In intestinal-cell experiments and a DSS mouse model, the targeted system reduced inflammatory and histologic measures. The investigators reported similar experimental efficacy with substantially less encapsulated KPV than free KPV solution.

A 2017 study added hyaluronic-acid functionalization to KPV-loaded nanoparticles. The formulation targeted colonic epithelial cells and macrophages and was evaluated in cell assays and groups of mice with DSS-induced colitis. The HA-functionalized system improved recovery in a wounded epithelial-cell layer and reduced selected inflammation and tissue-injury measurements in mice.

These are formulation-specific results. The active experiment included KPV, nanoparticle composition, hyaluronic-acid targeting, and a chitosan-alginate hydrogel. It cannot validate a differently made oral supplement, injection, cream, or nasal spray.

Does KPV repair the stomach lining?

The available studies do not establish that claim. They examined colonic epithelial cells, colon-targeted delivery, and mouse or rat models of colitis. These are colon models, not studies of the human stomach.

“Mucosal healing” in the 2017 paper referred to recovery in a wounded colonic epithelial-cell assay and tissue outcomes in mouse colitis. It did not refer to endoscopic healing in people and did not study gastritis, peptic ulcers, reflux disease, or gastric injury. The phrase should not be generalized into a human stomach-repair promise.

For related intestinal claims about another experimental peptide, see BPC-157 and IBD. That page applies the same distinction between animal injury models and human disease outcomes.

Does the cancer study show prevention?

No human cancer-prevention conclusion follows from the study. A 2016 paper examined PepT1 in a mouse model where azoxymethane plus DSS produces inflammation-associated colon tumors. KPV reduced tumor burden in wild-type mice, and the effect depended on PepT1. The same paper reported that lowering inflammation did not reduce tumor burden in the separate APC-Min genetic mouse model.

This is evidence about mechanism and model dependence, not evidence that KPV prevents or treats colorectal cancer in people. It would be unsafe to delay screening, diagnostic evaluation, or oncology care on the basis of these animal results.

Human evidence and safety gaps

FDA’s July 2026 compounding review is unusually useful because it separates commercial availability from evidence. FDA reported:

• no identified clinical studies or human exposure data for KPV by any route;
• no identified human pharmacokinetic or pharmacodynamic studies;
• insufficient clinical and nonclinical safety information;
• no adverse-event reports found in the searched systems, while explicitly warning that this does not imply safety; and
• no human data assessing immunogenicity or aggregation.

The original page’s safety language came from short cell-viability assays of specific nanoparticle formulations. A cell assay over hours or days cannot establish systemic toxicity, immune reactions, reproductive effects, interactions, infection risk, or chronic safety in humans.

KPV is also marketed in multiple forms. Oral, topical, intranasal, and injectable products create different exposure and manufacturing requirements. Evidence for one experimental delivery platform cannot fill the safety gaps for another route.

Regulatory status as of August 2026

KPV has no FDA-approved indication or FDA-approved drug product. At the July 2026 Pharmacy Compounding Advisory Committee meeting, FDA proposed that KPV free base and KPV acetate not be included on the section 503A Bulks List. FDA’s evaluation cited weak physical and chemical characterization, uncertain historical use, and the lack of human safety and effectiveness information.

An advisory-committee proceeding or a Bulks List proposal is not the same as an approved-drug review. It also does not make every online sale lawful or establish that a marketed product has the identity and quality claimed on its label. Regulatory status can change, so current FDA materials should be checked before publication or purchasing decisions.

Research-sourcing checks

For legitimate analytical or laboratory work, product evaluation should start with the exact material—not a general KPV marketing category.

1. Identity and termini: confirm the Lys-Pro-Val sequence and whether the N- and C-termini match the referenced experiment.
2. Free base versus acetate: record the salt or counterion form. FDA evaluated KPV free base and KPV acetate separately while noting characterization gaps.
3. Identity versus purity: mass spectrometry can support identity; chromatography can describe detected components. Neither alone establishes net quantity, sterility, endotoxin control, or biological activity.
4. Net peptide content: distinguish peptide assay from total vial mass, water, counterions, and excipients using a lot-specific report.
5. Formulation fidelity: document whether the research concerns free KPV, nanoparticles, hyaluronic-acid functionalization, or a hydrogel. These are not interchangeable interventions.
6. Route-specific quality: a research purity figure does not establish suitability for injection, intranasal use, oral use, or topical use.
7. Lot reconciliation: the vial label, lot number, analytical report, and quantity should match. A generic certificate cannot characterize every batch.

The source directory organizes public availability and batch-documentation signals; inclusion is not an endorsement for human use. Read the sourcing policy, peptide purity-testing guide, and research methodology before interpreting a listing.

Related reading

• KPV compound profile
• Healing Peptides: Evidence and Safety
• BPC-157 and Inflammatory Bowel Disease
• Use-Case Evidence Map
• Peptide Purity Testing
• Sourcing Policy
• Peptide Source Directory

References

1. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.
2. Laroui H, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010.
3. Xiao B, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy. 2017.
4. Viennois E, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of KPV in a murine model. Cellular and Molecular Gastroenterology and Hepatology. 2016.
5. Li W, et al. Self-cross-linked hydrogel stabilized KPV for TNBS-induced ulcerative colitis in rats. ACS Applied Materials & Interfaces. 2021.
6. US Food and Drug Administration. KPV-related bulk drug substances: safety and effectiveness review. 2026.
7. US Food and Drug Administration. July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting materials.

Bottom line

KPV has a plausible preclinical story: PepT1-mediated uptake, reduced inflammatory signaling, and improved outcomes in several experimental colitis systems. It does not yet have a human efficacy or safety story. The best current summary is “promising in cells and animal colon models, unestablished in people”—not “repairs the stomach,” “treats IBD,” or “prevents cancer.”

For research, match the material and delivery system to the paper and verify the exact lot. For health decisions, KPV should not replace diagnosis, cancer screening, or established treatment.